Okt3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation

Daniel Portela; Robin Patel; Jeffrey J. Larson-Keller; Duane M. Ilstrup; Russell H. Wiesner; Jeffery L. Steers; Ruud A.F. Krom; Carlos V. Paya

doi:10.1093/infdis/171.4.1014

Okt3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation

Daniel Portela, Robin Patel, Jeffrey J. Larson-Keller, Duane M. Ilstrup, Russell H. Wiesner, Jeffery L. Steers, Ruud A.F. Krom, Carlos V. Paya

Research output: Contribution to journal › Article › peer-review

115 Scopus citations

Abstract

The role of OKT3 monoclonal antibody administration was studied as a risk factor for symptomatic cytomegalovirus (CMV) infection in 229 consecutive liver transplant recipients not receiving specificCMV prophylaxis. Twenty-six patients (11.4%) receivedOKT3 and 17 ofthem developed CMV infection, 11 (4.8%) being symptomatic. OKT3 use was a significant risk factor for symptomatic CMV infection by both univariate (relative risk [RR], 2.9; 95% confidence interval [CI], 1.5-5.8; P =.002) and multivariate time-dependent (RR, 3.4; 95% CI, 1.7-7.1; P =.001) analyses. A subgroup analysis revealed that OKT3 use was a significant risk factor for symptomatic CMV infection in CMV-seropositive but not seronegative recipients. OKT3 therapy for steroid-resistant rejection is a risk factor for symptomatic CMV infection in liver transplant recipients who are seropositive for CMV before transplantation. This group should be targeted for antiviral prophylaxis when OKT3 antirejection therapy is used.

Original language	English (US)
Pages (from-to)	1014-1018
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	171
Issue number	4
DOIs	https://doi.org/10.1093/infdis/171.4.1014
State	Published - Apr 1995

ASJC Scopus subject areas

General Medicine

Access to Document

10.1093/infdis/171.4.1014

Cite this

@article{452505f281b54e25a4f4587de0a01abf,

title = "Okt3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation",

abstract = "The role of OKT3 monoclonal antibody administration was studied as a risk factor for symptomatic cytomegalovirus (CMV) infection in 229 consecutive liver transplant recipients not receiving specificCMV prophylaxis. Twenty-six patients (11.4%) receivedOKT3 and 17 ofthem developed CMV infection, 11 (4.8%) being symptomatic. OKT3 use was a significant risk factor for symptomatic CMV infection by both univariate (relative risk [RR], 2.9; 95% confidence interval [CI], 1.5-5.8; P =.002) and multivariate time-dependent (RR, 3.4; 95% CI, 1.7-7.1; P =.001) analyses. A subgroup analysis revealed that OKT3 use was a significant risk factor for symptomatic CMV infection in CMV-seropositive but not seronegative recipients. OKT3 therapy for steroid-resistant rejection is a risk factor for symptomatic CMV infection in liver transplant recipients who are seropositive for CMV before transplantation. This group should be targeted for antiviral prophylaxis when OKT3 antirejection therapy is used.",

author = "Daniel Portela and Robin Patel and Larson-Keller, {Jeffrey J.} and Ilstrup, {Duane M.} and Wiesner, {Russell H.} and Steers, {Jeffery L.} and Krom, {Ruud A.F.} and Paya, {Carlos V.}",

year = "1995",

month = apr,

doi = "10.1093/infdis/171.4.1014",

language = "English (US)",

volume = "171",

pages = "1014--1018",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Okt3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation

AU - Portela, Daniel

AU - Patel, Robin

AU - Larson-Keller, Jeffrey J.

AU - Ilstrup, Duane M.

AU - Wiesner, Russell H.

AU - Steers, Jeffery L.

AU - Krom, Ruud A.F.

AU - Paya, Carlos V.

PY - 1995/4

Y1 - 1995/4

N2 - The role of OKT3 monoclonal antibody administration was studied as a risk factor for symptomatic cytomegalovirus (CMV) infection in 229 consecutive liver transplant recipients not receiving specificCMV prophylaxis. Twenty-six patients (11.4%) receivedOKT3 and 17 ofthem developed CMV infection, 11 (4.8%) being symptomatic. OKT3 use was a significant risk factor for symptomatic CMV infection by both univariate (relative risk [RR], 2.9; 95% confidence interval [CI], 1.5-5.8; P =.002) and multivariate time-dependent (RR, 3.4; 95% CI, 1.7-7.1; P =.001) analyses. A subgroup analysis revealed that OKT3 use was a significant risk factor for symptomatic CMV infection in CMV-seropositive but not seronegative recipients. OKT3 therapy for steroid-resistant rejection is a risk factor for symptomatic CMV infection in liver transplant recipients who are seropositive for CMV before transplantation. This group should be targeted for antiviral prophylaxis when OKT3 antirejection therapy is used.

AB - The role of OKT3 monoclonal antibody administration was studied as a risk factor for symptomatic cytomegalovirus (CMV) infection in 229 consecutive liver transplant recipients not receiving specificCMV prophylaxis. Twenty-six patients (11.4%) receivedOKT3 and 17 ofthem developed CMV infection, 11 (4.8%) being symptomatic. OKT3 use was a significant risk factor for symptomatic CMV infection by both univariate (relative risk [RR], 2.9; 95% confidence interval [CI], 1.5-5.8; P =.002) and multivariate time-dependent (RR, 3.4; 95% CI, 1.7-7.1; P =.001) analyses. A subgroup analysis revealed that OKT3 use was a significant risk factor for symptomatic CMV infection in CMV-seropositive but not seronegative recipients. OKT3 therapy for steroid-resistant rejection is a risk factor for symptomatic CMV infection in liver transplant recipients who are seropositive for CMV before transplantation. This group should be targeted for antiviral prophylaxis when OKT3 antirejection therapy is used.

UR - http://www.scopus.com/inward/record.url?scp=0028947037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028947037&partnerID=8YFLogxK

U2 - 10.1093/infdis/171.4.1014

DO - 10.1093/infdis/171.4.1014

M3 - Article

C2 - 7706779

AN - SCOPUS:0028947037

SN - 0022-1899

VL - 171

SP - 1014

EP - 1018

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 4

ER -

Okt3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this